TL;DR: The Centers for Medicare & Medicaid Services reaffirmed NCD 319, its national coverage determination on blood brain barrier osmotic disruption for brain tumors — and the verdict hasn't changed since 2007: this procedure is not covered under Medicare.
CMS modified NCD 319 (policy key 319-v1) effective January 9, 2026, confirming that osmotic blood brain barrier disruption (BBBD) remains nationally non-covered for brain tumor treatment. The policy does not list specific CPT or HCPCS codes. Billing teams submitting claims for osmotic BBBD in any Medicare context should expect denial.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Blood Brain Barrier Osmotic Disruption for Treatment of Brain Tumors |
| Policy Code | NCD 319 |
| Change Type | Modified |
| Effective Date | 2026-01-09 |
| Impact Level | Medium — low claim volume, but high denial risk and significant revenue exposure per case |
| Specialties Affected | Neurosurgery, Neuro-oncology, Inpatient Hospital Billing, Oncology |
| Key Action | Flag and deny-on-submission any claims for osmotic BBBD on Medicare patients; confirm chemotherapy codes are billed separately and correctly |
CMS Blood Brain Barrier Disruption Coverage Criteria and Medical Necessity Requirements 2026
The CMS blood brain barrier disruption coverage policy is one of the clearest non-coverage positions in the NCD catalog. There are no covered indications. None.
The Centers for Medicare & Medicaid Services determined — effective March 20, 2007 — that osmotic BBBD is "not reasonable and necessary" when used as part of a brain tumor treatment regimen. That language is the standard CMS medical necessity threshold, and this procedure doesn't clear it. The 2026 modification reaffirms that position without softening it.
This matters for medical necessity documentation: no amount of supporting clinical notes will convert a non-covered NCD into a payable claim. NCD 319 is a hard national non-coverage determination. It preempts any local coverage determination (LCD) from a Medicare Administrative Contractor (MAC). If your MAC has issued anything that seems to soften this, it doesn't override the NCD.
Prior authorization is not applicable here — you can't get prior auth approval for a nationally non-covered service. If a patient wants osmotic BBBD and is on Medicare, the conversation starts with an Advance Beneficiary Notice of Noncoverage (ABN), not a prior auth request.
One important boundary the policy draws clearly: NCD 319 does not alter coverage of anti-cancer chemotherapy. The disruption procedure itself is non-covered. The chemotherapy drugs given alongside BBBD are governed by their own coverage rules. Don't let the non-coverage of the disruption procedure contaminate your chemotherapy billing.
CMS Blood Brain Barrier Disruption Exclusions and Non-Covered Indications
The entire indication category — osmotic BBBD as part of any brain tumor treatment regimen — is non-covered. There is no approved subset. Primary brain tumors, metastatic brain tumors, any tumor type: all non-covered.
The policy describes osmotic disruption as the most common BBBD technique. It also references bradykinin and irradiation-based disruption methods. NCD 319 specifically addresses osmotic disruption. The non-coverage language ties to "osmotic BBBD" used "as part of a treatment regimen for brain tumors."
If your team is billing for a bradykinin or irradiation-based BBB disruption approach, NCD 319 technically addresses only the osmotic method. That doesn't mean the others are covered — it means NCD 319 doesn't govern them. Talk to your compliance officer before billing those claims under any assumption of coverage. The medical necessity standard still applies, and there is no nationally covered indication for any BBB disruption method under current CMS policy.
The BBBD process, per the policy's own definition, includes all items and services necessary to perform the procedure. That bundled scope matters for billing. Hospitalization tied to the procedure, monitoring during disruption, and repeated imaging performed as part of the BBBD process — all of it falls under the non-covered umbrella when it's part of the BBBD regimen. Don't unbundle those components and bill them separately expecting reimbursement. You'll get a denial on the core procedure and scrutiny on the ancillaries.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Osmotic BBBD for primary brain tumors | Not Covered | Not listed in NCD | Non-covered effective March 20, 2007; reaffirmed 2026 |
| Osmotic BBBD for metastatic brain tumors | Not Covered | Not listed in NCD | Same national non-coverage determination applies |
| Osmotic BBBD as part of any brain tumor treatment regimen | Not Covered | Not listed in NCD | Bundled services (hospitalization, monitoring, imaging) also non-covered when performed as part of BBBD |
| Anti-cancer chemotherapy (standalone) | Not addressed by NCD 319 | Governed by separate coverage policy | NCD 319 explicitly does not alter chemotherapy coverage |
CMS Blood Brain Barrier Disruption Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Audit your charge master and charge capture for any BBBD-related codes before processing claims dated on or after January 9, 2026. If your team has been building claims for osmotic BBBD on Medicare patients, stop now. Every one of those claims will generate a claim denial under NCD 319. |
| 2 | Issue Advance Beneficiary Notices (ABNs) for any Medicare patient who requests osmotic BBBD. Since this is a nationally non-covered service, the ABN protects your organization and informs the patient. This is not optional — it's the required step before providing a non-covered service to a Medicare beneficiary who may want to pay out of pocket. |
| 3 | Separate your chemotherapy billing from the BBBD procedure billing. The policy is explicit: NCD 319 does not affect chemotherapy coverage. Bill chemotherapy claims under their applicable coverage rules. Do not associate them with the BBBD claim in a way that creates denial risk by proximity. |
| 4 | Do not unbundle the components of a BBBD encounter and bill them independently. Hospitalization, monitoring, and imaging performed as part of the BBBD process are part of the non-covered service bundle. Billing them separately as if they occurred outside the BBBD context invites a fraud and abuse exposure. If you're unsure how to handle a mixed encounter — some services tied to BBBD, some not — loop in your compliance officer before submitting. |
| 5 | Check whether any open claims or pending remittances exist for BBBD services billed under Medicare. The effective date of this modification is January 9, 2026, but the underlying non-coverage dates to March 20, 2007. Any claims already in the system for osmotic BBBD on Medicare patients should be reviewed. If they haven't been denied yet, they will be. Get ahead of it. |
| 6 | Confirm with your MAC whether any local coverage determination addresses BBBD techniques other than osmotic disruption. NCD 319 covers osmotic disruption specifically. If your practice is involved in any clinical trial or emerging protocol using bradykinin or irradiation-based BBB disruption, contact your MAC directly. An NCD gap is not the same as coverage. The absence of an NCD on a topic means your MAC's LCD — or lack of one — governs the claim. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Blood Brain Barrier Disruption Under NCD 319
Covered CPT Codes
NCD 319 does not list any covered CPT or HCPCS codes. There are no nationally covered indications under this policy.
Not Covered — No Specific Codes Listed
The policy does not enumerate specific CPT or HCPCS codes for osmotic BBBD. CMS has not published procedure-specific code assignments within NCD 319 itself.
This is a known challenge with older NCDs — the original determination predates the current code environment, and CMS has not issued a companion claims processing instruction that maps specific codes to this NCD. That doesn't create a billing loophole. The non-coverage applies to the procedure regardless of which code is used to represent it on a claim.
Practical Coding Guidance
Because no codes are enumerated in NCD 319, osmotic BBBD billing typically falls to unlisted procedure codes or exploratory surgical codes depending on context. Your MAC may have specific coding guidance in a separate transmittal or claims processing instruction. Check the CMS Claims Processing Manual and contact your MAC before assuming a code is outside the scope of this NCD.
The absence of specific codes in the policy data does not change the non-coverage finding. If your coding team is using any code to represent osmotic blood brain barrier disruption on a Medicare claim, that claim is non-covered under NCD 319.
Why This Policy Matters More Than It Looks
Osmotic BBBD is not a high-volume procedure in most billing departments. But that's exactly when these claims become expensive. Low-volume procedures fly under the charge capture radar. One or two claims per year at inpatient rates — with bundled hospitalization and imaging — can represent significant reimbursement exposure when they come back as denials or, worse, as overpayments flagged in a post-payment audit.
The 2026 modification didn't add new restrictions. It didn't remove any. This is a reaffirmation of a nearly two-decade-old non-coverage position. The risk isn't a sudden policy shift — it's that your billing team may not know this NCD exists.
This is the same pattern you see with certain gene therapy billing and some experimental oncology procedures: CMS plants a hard non-coverage flag, years pass, the procedure resurfaces in a clinical context, and someone bills it without realizing the NCD is still active. That's how you end up with a post-payment audit finding on a service that was never covered.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.